Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open RoAD: Long-Term Gantenerumab Rollover Study
NCT04339413Phase 3Terminated
- Sponsor
- Roche
- Start
- May 2020
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
Phase 3, open-label trial of gantenerumab in Alzheimer's disease (AD) (2 arms), sponsored by Roche. Primary endpoints: Number of Participants With Adverse Events and Serious Adverse Events, Number of Participants With Change in Any Suicidal Ideation or Behavior as Assessed by C-SSRS and 5 more. Started May 2020; status: terminated.
02
Drugs
gantenerumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04339413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04339413.